{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T21:57:50Z","timestamp":1783720670213,"version":"3.55.0"},"reference-count":30,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To assess how long participants with type 2 diabetes spent with HbA1c\u2009less than 7.0% and how likely they were to maintain this target\u00a0with oral semaglutide 7\u2009mg versus sitagliptin 100\u2009mg or oral semaglutide 14\u2009mg versus empagliflozin 25\u2009mg, sitagliptin 100\u2009mg or subcutaneous liraglutide 1.8\u2009mg.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>\n                      Analyses used on\u2010treatment data without rescue medication for all randomized participants (semaglutide [approved maintenance doses],\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091880; comparators [not including placebo],\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091412). Duration of time with HbA1c\u2009less than\u20097.0% was calculated using an HbA1c time curve. A binary endpoint of achieving HbA1c\u2009less than 7.0% at weeks 26 (week 24 for PIONEER 7) and 52 of each trial (and week 78 for PIONEER 3) was analysed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Mean duration of time with HbA1c\u2009less than 7.0% was greater with oral semaglutide 7\u2009mg versus sitagliptin in PIONEER 3 (27 vs. 22\u2009weeks) and with oral semaglutide 14\u2009mg versus empagliflozin and sitagliptin (27\u201034 vs. 19 vs. 22\u2009weeks, respectively), and similar versus subcutaneous liraglutide. A greater proportion of participants achieved and maintained HbA1c\u2009less than\u20097.0% for more than 75% of the trial with oral semaglutide 14\u2009mg versus oral comparators. The odds of achieving HbA1c\u2009less than\u20097.0% at weeks 24\/26 and 52\/78 were significantly greater with oral semaglutide 14\u2009mg versus oral comparators or subcutaneous liraglutide, and with oral semaglutide 7\u2009mg versus sitagliptin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Oral semaglutide 7 and 14\u2009mg resulted in greater time spent with HbA1c\u2009less than\u20097.0%, and a greater likelihood of achieving and maintaining HbA1c less than\u20097.0% versus oral comparators.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.15339","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T20:35:46Z","timestamp":1699389346000},"page":"532-539","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Greater time spent with\n                    <scp>HbA1c<\/scp>\n                    \u2009less than\u20097.0% with oral semaglutide versus oral comparators: An exploratory analysis of the\n                    <scp>PIONEER<\/scp>\n                    studies"],"prefix":"10.1111","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8324-3275","authenticated-orcid":false,"given":"Julio","family":"Rosenstock","sequence":"first","affiliation":[{"name":"Velocity Clinical Research at Medical City  Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-8040","authenticated-orcid":false,"given":"Bertrand","family":"Cariou","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, CHU Nantes, CNRS, Inserm, l'institut du thorax  Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Eliasson","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Frappin","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margit S.","family":"Kaltoft","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2518-9076","authenticated-orcid":false,"given":"Eduard","family":"Montanya","sequence":"additional","affiliation":[{"name":"Hospital Universitari Bellvitge, IDIBELL, CIBERDEM, and University of Barcelona  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2495-5034","authenticated-orcid":false,"given":"Filip K.","family":"Knop","sequence":"additional","affiliation":[{"name":"Center for Clinical Metabolic Research, Gentofte Hospital University of Copenhagen  Hellerup Denmark"},{"name":"Steno Diabetes Center Copenhagen  Herlev Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences University of Copenhagen  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,11,7]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-S009"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0034"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.4158\/CS-2019-0472"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-S006"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806470"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802987"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-4082-5"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-051X.1988.tb01003.x"},{"key":"e_1_2_10_10_1","unstructured":"U.S. Food and Drug Administration.Ozempic\u00ae prescribing information. Accessed May 11 2023.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/209637s008lbl.pdf"},{"key":"e_1_2_10_11_1","unstructured":"European Medicines Agency.Ozempic\u00ae (semaglutide) European summary of product characteristics. Accessed May 11 2023.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ozempic-epar-product-information_en.pdf"},{"key":"e_1_2_10_12_1","unstructured":"U.S. Food and Drug Administration.Rybelsus\u00ae prescribing information. Accessed May 11 2023.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/213051s006lbl.pdf"},{"key":"e_1_2_10_13_1","unstructured":"European Medicines Agency.Rybelsus\u00ae (semaglutide) European summary of product characteristics. Accessed May 11 2023.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rybelsus-epar-product-information_en.pdf"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.05.009"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14244"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0749"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30192-5"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30194-9"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31271-1"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0883"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.2942"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0898"},{"issue":"1","key":"e_1_2_10_23_1","first-page":"S1","article-title":"Time spent in glycaemic control after initiating treatment with oral semaglutide vs empagliflozin: an exploratory analysis of the PIONEER 2 trial (abstract)","volume":"64","author":"Knop FK","year":"2021","journal-title":"Diabetologia"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13088"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30013-X"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30092-X"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0417"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14566"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2200433"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/nutd.2017.31"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-2415"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.15339","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:47:25Z","timestamp":1761868045000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.15339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,7]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1111\/dom.15339"],"URL":"https:\/\/doi.org\/10.1111\/dom.15339","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.15339\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15339\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15339\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15339\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15339\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15339\/v2\/decision1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,7]]},"assertion":[{"value":"2023-07-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}